Introduction
CLL treatment landscape, Available treatment options for a R/R CLL, CLL-321 data, incl target patient
Objectives
To equip healthcare professionals with the latest knowledge on novel therapeutic strategies for managing patients with Chronic Lymphocytic Leukemia.
Participants will be able to differentiate between first-line, second-line, and relapsed/refractory treatment options for Chronic Lymphocytic Leukemia.
Participants will be able to explain the rationale behind using BTK inhibitors in CLL treatment.
Participants will be able to identify the various targeted therapies currently approved for CLL.
This Course For :
Physician
( Hematology , Oncology )
Resident / Fellow
( Hematology , Oncology )
Speaker
MICHAEL PAPADIMITRIOUS
Medical Affairs Professional Hematology, Oncology, Eli Lilly
Dr. Danielle Leão
Hematologist and Clinical researcher in Hematological Diseases at Beneficência Portuguesa de Sao Paulo, Brazil
Dr. Lucrecia Yañez
Associate Professor at the University of Cantabria, Spain
Prof. Clemens Wendtner
Professor of Medicine and Chief Physician at Munich Clinic Schwabing, Germany
Prof. Paolo Ghia
Professor at the Università Vita-Salute San Raffaele Milan, Italy
Provided by :
Price
Course Fee
FREE
FREE
Contact Information
Organization : Virtual Medical AcademyPhone : 920008161
Email : [email protected]
Free
11 Nov 2025 To 11 Nov 2025 -
06:00 PM To 07:00 PM 
Certificate Available 
Online
Add to Calendar
11/11/2025 06:00 PM
11/11/2025 07:00 PM
Asia/ Riyadh
HEMA TALKs: The Crossroads of CLL Relapse – Mapping the Path Forward with Jaypirca
HEMA TALKs: The Crossroads of CLL Relapse – Mapping the Path Forward with Jaypirca
https://medicalacademy.org/portal/event/view/2446
